Infinity exercises option to buy all future royalty obligations to Takeda for Duvelisib
Infinity Pharmaceuticals announced it has exercised its option to buy out all future royalty obligations due to Takeda for sales of duvelisib (IPI-145), Infinity’s dual inhibitor of phosphoinositide-3-kinase-delta and PI3K-gamma, in oncology indications. March 31, 2015